Richard Wooster
InvestorExecutive Partner at Syncona
About
Richard Wooster is an Executive Partner of Syncona Investment Management Ltd and serves as Chief Scientific Officer and a Director of Slingshot Therapeutics. He previously held Chief Scientific Officer roles at Translate Bio (acquired by Sanofi in 2021) and Tarveda Therapeutics, and led oncology discovery as a Vice President at GlaxoSmithKline. He began his career at the Institute of Cancer Research, where he discovered the BRCA2 gene, and helped found the Cancer Genome Project at the Wellcome Trust Sanger Institute; he holds a PhD from the University of Dundee.
Invests in
Biotech
Investments
Board seats
Slingshot Therapeutics
Per the firm's website.
Colleagues at Syncona
Frequently asked questions
- Who is Richard Wooster?
- Richard Wooster is an Executive Partner of Syncona Investment Management Ltd and serves as Chief Scientific Officer and a Director of Slingshot Therapeutics. He previously held Chief Scientific Officer roles at Translate Bio (acquired by Sanofi in 2021) and Tarveda Therapeutics, and led oncology discovery as a Vice President at GlaxoSmithKline. He began his career at the Institute of Cancer Research, where he discovered the BRCA2 gene, and helped found the Cancer Genome Project at the Wellcome Trust Sanger Institute; he holds a PhD from the University of Dundee.
- Where does Richard Wooster work?
- Richard Wooster is Executive Partner at Syncona.
- What does Richard Wooster invest in?
- Richard Wooster invests in Biotech.
- What boards does Richard Wooster sit on?
- Richard Wooster holds tracked board seats at Slingshot Therapeutics.